½ÃÀ庸°í¼­
»óǰÄÚµå
1621851

qPCR Àåºñ ½ÃÀå ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)

qPCR Instruments Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 135 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è qPCR Àåºñ ½ÃÀåÀº 2023³â 16¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024-2032³â°£ ¿¬Æò±Õ 8.4% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â Áúº´ À¯º´·ü Áõ°¡¿Í °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡¸¦ µé ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ´Ù¾çÇÑ Áúº´ÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó qPCR°ú °°Àº ½Ç½Ã°£ Á¤·®È­ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ½Å¼ÓÇϰí Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇϱ⠶§¹®¿¡ °¨¿°¼º Áúȯ, ¾Ï, À¯Àü¼º ÁúȯÀÇ Áø´Ü ¹× ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀÔ´Ï´Ù. µµ½ÃÈ­, °í·ÉÈ­, »ýȰ½À°ü º¯È­ µîÀÇ ¿äÀÎÀÌ ºñ°¨¿°¼º Áúȯ Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ƯÈ÷ °¨¿° ¹× ¸¸¼ºÁúȯ ¹ß»ý·üÀÌ ³ôÀº Áö¿ª¿¡¼­´Â qPCR ±â¼úÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö´Â °Íµµ qPCR Àåºñ ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¸ÂÃãÀÇ·á´Â Á¤¹ÐÇÑ ºÐÀÚÁø´Ü¿¡ ÀÇÁ¸Çϰí ÀÖÀ¸¸ç, qPCRÀº »ó¼¼ÇÑ À¯ÀüÀÚ ÇÁ·ÎÆÄÀϸµ°ú ½Ç½Ã°£ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ´É·ÂÀº ¸ÂÃã Ä¡·áÀÇ °³¹ß, À¯ÀüÀÚ º¯ÀÌ ½Äº°, ȯÀÚº° ¸ÂÃã Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¸ÂÃãÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó, ÀǾàǰ °³¹ß ¹× Ç¥ÀûÄ¡·á¿Í °°Àº ºÐ¾ß¿¡¼­ qPCRÀÇ ¿ªÇÒÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â qPCR ½Ã½ºÅÛ ºÎ¹®ÀÌ 2023³â 6¾ï 4,420¸¸ ´Þ·¯·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. qPCR ½Ã½ºÅÛÀº ½Ç½Ã°£ PCR °Ë»çÀÇ ÇÙ½ÉÀ̸ç Áø´Ü, ¿¬±¸ ¹× ÀǾàǰ °³¹ß¿¡¼­ Á¤·® ºÐ¼®¿¡ Áß¿äÇÑ Ç÷§ÆûÀ» ¼³¸íÇÕ´Ï´Ù. qPCR ½Ã½ºÅÛÀº ±¸¸Å ¹× ½ÇÇè½Ç, º´¿ø ¹× Ŭ¸®´Ð¿¡ ¼³Ä¡ÇÏ´Â µ¥ ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ½ÃÀå¿¡¼­ °¡Àå ÀÚº» Áý¾àÀû ÀÎ ºÎ¹®ÀÔ´Ï´Ù. ÀÔ´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ Àåºñ´Â ´Ù¾çÇÑ ¿ëµµ·Î ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ¾î Àüü ¼öÀÍ¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2023³â
¿¹Ãø ¿¬µµ 2024³â-2032³â
½ÃÀÛ ±Ý¾× 1.6¾ï ´Þ·¯
¿¹»ó ±Ý¾× 33¾ï ´Þ·¯
CAGR 8.4%

¿ëµµº°·Î´Â À¯ÀüÀÚ ¹ßÇö, À¯ÀüÀÚÇü ºÐ¼®, º´¿øÃ¼ °ËÃâ, Áø´Ü, ±âŸ·Î ±¸ºÐµÇ¸ç, 2023³â À¯ÀüÀÚ ¹ßÇö ºÎ¹®ÀÌ 26.6%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯ÀüÀÚ ¹ßÇö ºÐ¼®Àº ºÐÀÚ»ý¹°Çп¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, ƯÈ÷ ¾Ï ¿¬±¸, ÀǾàǰ °³¹ß, Áúº´ ¸ÞÄ¿´ÏÁò ¿¬±¸ µî ´Ù¾çÇÑ Á¶°Ç¿¡¼­ À¯ÀüÀÚ Á¶Àý ¹× ¹ßÇöÀ» ÀÌÇØÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ qPCR Àåºñ´Â ÀÌ·¯ÇÑ ¿ëµµ¿¡ ÇʼöÀûÀ̸ç Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â 6¾ï 2,100¸¸ ´Þ·¯·Î 2032³â±îÁö ¿¬Æò±Õ 8.1% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, HIV, µ¶°¨, Äڷγª19¿Í °°Àº °¨¿°¼º ÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. qPCR Àåºñ´Â Á¤È®¼º°ú ¼Óµµ·Î Àß ¾Ë·ÁÁ® ÀÖÀ¸¸ç, º´¿ø±ÕÀ» ½Å¼ÓÇÏ°Ô °¨ÁöÇÏ¿© ÀÇ·áÁøÀÌ Áúº´ ¹ß»ýÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • »ê¾÷¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Áúº´ Áõ°¡
      • ±â¼ú Áøº¸
      • ¸ÂÃãÇü ÀÇ·á Áß½Ã
      • ÀÓ»ó½ÃÇè¼öʱâ°ü(CRO) ¼ºÀå
    • »ê¾÷ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
      • µð¹ÙÀ̽º °íºñ¿ë
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • °¸ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Á¦Ç° À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • qPCR ½Ã½ºÅÛ
  • ½Ã¾à ¹× ¼Ò¸ðǰ
  • ¼ÒÇÁÆ®¿þ¾î

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • À¯ÀüÀÚ ¹ßÇö
  • Áö³ëŸÀÌÇÎ
  • º´¿øÃ¼ °ËÃâ
  • Áø´Ü
  • ±âŸ

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Áø´Ü½ÇÇè½Ç
  • º´¿ø ¹× Ŭ¸®´Ð
  • Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Azure Biosystems Inc.
  • Bio Molecular Systems
  • BIOMERIEUX SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eppendorf
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • QIAGEN N.V.
  • Quantabio
  • Siemens Healthineers AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
LSH 25.01.10

The Global qPCR Instruments Market was valued at USD 1.6 billion in 2023 and is projected to grow at a CAGR of 8.4% from 2024 to 2032. Key drivers for this growth include the rising prevalence of diseases and an increasing focus on personalized medicine. The growing incidence of various diseases worldwide has significantly boosted the demand for real-time quantification tools like qPCR. These tools are crucial for diagnosing and monitoring infectious diseases, cancer, and genetic disorders due to their ability to provide rapid and accurate results. Factors such as urbanization, aging populations, and lifestyle changes have contributed to the rise in non-communicable diseases, further driving the need for qPCR technology, especially in areas with high rates of infections and chronic conditions.

The rising focus on personalized medicine is also a key factor propelling the qPCR instruments market. Personalized medicine relies on precise molecular diagnostics, and qPCR enables detailed genetic profiling and real-time monitoring. This capability is essential for developing individualized treatments, identifying genetic mutations, and tailoring therapies to meet the specific needs of patients. As the demand for personalized therapies continues to grow, qPCR's role in areas like drug development and targeted treatments is becoming more prominent, supporting market expansion.

In terms of product types, the qPCR systems segment led the market in 2023, generating USD 644.2 million. These systems are the backbone of real-time PCR testing, providing critical platforms for quantitative analysis in diagnostics, research, and drug development. qPCR systems are the most capital-intensive segment of the market, given the substantial investment required for their purchase and installation in labs, hospitals, and clinics. However, these machines are extensively utilized for various applications, making them a key contributor to overall revenue.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$1.6 Billion
Forecast Value$3.3 Billion
CAGR8.4%

Based on application, the market is segmented into gene expression, genotyping, pathogen detection, diagnostics, and others. In 2023, the gene expression segment held the largest share, at 26.6%. Gene expression analysis plays a key role in molecular biology, helping researchers understand gene regulation and expression under various conditions, particularly in cancer research, drug development, and disease mechanism studies. This makes qPCR instruments vital for such applications, driving consistent demand.

Regionally, North America accounted for USD 621 million in 2023 and is expected to grow at a CAGR of 8.1% through 2032. The rising incidence of infectious diseases like HIV, influenza, and COVID-19 has significantly increased the demand for advanced diagnostic tools in the region. qPCR instruments, known for their accuracy and speed, are instrumental in detecting pathogens quickly, enabling healthcare providers to manage disease outbreaks effectively.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Emphasis on personalized medicine
      • 3.2.1.4 Growth of contract research organizations (CROs)
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of devices
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 qPCR systems
  • 5.3 Reagents and consumables
  • 5.4 Software

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Gene expression
  • 6.3 Genotyping
  • 6.4 Pathogen detection
  • 6.5 Diagnostics
  • 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Diagnostics laboratories
  • 7.3 Hospitals & clinics
  • 7.4 Pharma & biotech companies
  • 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 Agilent Technologies, Inc.
  • 9.3 Azure Biosystems Inc.
  • 9.4 Bio Molecular Systems
  • 9.5 BIOMERIEUX SA
  • 9.6 Bio-Rad Laboratories, Inc.
  • 9.7 Danaher Corporation
  • 9.8 Eppendorf
  • 9.9 F. Hoffmann-La Roche Ltd.
  • 9.10 Merck KGaA
  • 9.11 QIAGEN N.V.
  • 9.12 Quantabio
  • 9.13 Siemens Healthineers AG
  • 9.14 Takara Bio Inc.
  • 9.15 Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦